Boehringer Ingelheim has pursued a series of licensing agreements in early 2026 while maintaining an active search for additional external innovation opportunities, according to company leadership.
The year began with a deal valued at over $120 million in potential payments with Variant Bio to identify new targets for cardiorenal and kidney diseases. This followed another kidney-focused collaboration signed weeks earlier with Rectify Pharmaceuticals, which could reach up to $448 million for work on a preclinical program.
By the end of January, the company had secured a 1.05 billion euro ($1.26 billion) agreement with Simcere for a preclinical bispecific antibody targeting inflammatory bowel disease. In February, Boehringer added a $500 million partnership with Sitryx focused on developing oral treatments for autoimmune and inflammatory conditions.
Despite these additions, Paola Casarosa indicated that further dealmaking remains a priority. “Our key focus is on T-cell engagers, as well as ADCs,” she said in an interview.
These priorities align with ongoing internal programs. The company recently advanced its DLL3/DC3 T-cell engager, obrixtamig, into a phase 3 study for small-cell lung cancer. In the antibody-drug conjugate (ADC) space, Boehringer previously licensed a candidate from AimedBio in a deal worth up to $991 million and invested approximately $31 million in a Switzerland-based research facility dedicated to ADC development. Casarosa noted that the company continues to explore next-generation payloads and new methods of linking them to antibodies.
Additional areas under consideration include bispecific and trispecific antibodies, along with in-vivo CAR-T therapies. Casarosa highlighted increasing activity in emerging technology platforms, particularly in China, and pointed to growing interest in applying oncology-derived approaches such as CAR-T and T-cell engagers to autoimmune diseases. She stated that Boehringer intends to explore these applications, while noting the need for careful attention to tolerability and side effects.
When sourcing new assets, the company generally favors preclinical-stage opportunities. Casarosa explained that earlier collaboration allows for closer joint development, while also reflecting the rising cost of later-stage assets. She described the current environment as competitive, with multiple companies seeking to strengthen their pipelines, adding that Boehringer is not reliant on late-stage acquisitions and can pursue more flexible approaches.
Although recent activity has centered on partnerships, the company has not ruled out acquisitions. Casarosa referenced past purchases, including T3 Pharmaceuticals in 2023 and Amal Therapeutics in 2019, emphasizing that decisions depend on whether a full company or a single asset is the better strategic fit.
Financially, Boehringer reported research and development spending of 6.4 billion euros ($7.4 billion) in 2025, representing an 8.3% increase year over year. This accounted for 22.9% of its 27.8 billion euros ($32 billion) in sales. Chief Financial Officer Frank Hübler described the ratio as above peer levels.
The company disclosed these figures during a March 25 press conference at its headquarters in Ingelheim, Germany. The site spans 762,000 square meters and employs around 10,000 people. It includes both long-standing manufacturing facilities and new infrastructure, such as a seven-story chemical innovation plant scheduled to open in 2027.
Founded in 1885, Boehringer has grown from a small operation producing tartaric acid salts into a global organization with approximately 54,000 employees across 76 countries. It remains owned by the family of its founder, Albert Boehringer.
Among its current clinical programs, the company is advancing survodutide, a GLP-1/glucagon agonist developed in partnership with Zealand Pharma, with phase 3 data expected this year. Mid-stage results showed nearly 19% weight loss at 46 weeks, while a separate study reported up to 83% of participants achieving statistically significant improvement in metabolic dysfunction-associated steatohepatitis.
Boehringer has also recorded recent regulatory milestones, including approval of Hernexeos for HER2-mutated lung cancer and Jascayd for idiopathic pulmonary fibrosis. These developments contributed to a 7.4% increase in human pharmaceutical sales, supported by the continued growth of existing products such as Jardiance and Ofev.
Casarosa stated that these approvals have provided renewed momentum for the company’s research organization, reinforcing its continued focus on innovation.
Overview of Boehringer Ingelheim Strategy
Boehringer Ingelheim is actively expanding its dealmaking activities as it sharpens its focus on next-generation cancer therapies. The latest moves highlight how Boehringer Ingelheim is prioritizing innovation in T-cell engagers and antibody-drug conjugates (ADCs), two of the most promising areas in oncology.
Why Boehringer Ingelheim Is Targeting T-Cell Engagers
Boehringer Ingelheim is increasingly investing in T-cell engager technologies due to their ability to harness the immune system to attack cancer cells. These therapies offer high precision and effectiveness, making them a strategic priority for Boehringer Ingelheim as it builds a differentiated oncology pipeline.
Boehringer Ingelheim Focus on ADCs
Antibody-drug conjugates (ADCs) are another key focus area for Boehringer Ingelheim. By combining targeted antibodies with potent cytotoxic agents, ADCs provide a powerful approach to cancer treatment. Boehringer Ingelheim aims to leverage this modality to enhance treatment outcomes while minimizing side effects.
